ERAS
ErascaยทNASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
ERAS Profile
Erasca, Inc.
A clinical-stage precision oncology company that develops therapies for RAS/MAPK pathway-driven cancers
3115 Merryfield Row, Suite 300, San Diego, CA 92121
--
Erasca, Inc., was incorporated in Delaware on July 2, 2018. The company is a clinical-stage precision oncology company focused on discovering, developing and commercializing therapies for cancer patients driven by the RAS/MAPK pathway. Co-founded by leading pioneers in precision oncology and RAS targeting, the company aims to create new therapies and combination programs aimed at completely shutting down the RAS/MAPK pathway to treat cancer.
